All Publications

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights from the Department of Veterans Affairs

2017

Article

Additional authors and institutional affiliations

Circulation (2017) 135(25):2572-2574

Available to BHSF community via local IP address or BHSF login.

COinS